GoldenGolden
Advanced Search
SpyBiotech

SpyBiotech

A biomedical company in United Kingdom that develops vaccines and vaccine development technology

SpyBiotech is a biomedical company in United Kingdom that developed a method to bind antigens to virus like particles (VLPs) for vaccine development. The company focuses on producing vaccines more quickly, cheaply and effectively. Founded 2017 in Oxford, Oxfordshire, United Kingdom by Sumi Biswas, SpyBiotech has raised a total of £4M in funding over one round. This was a seed round raised on March 30, 2017. The company is funded by two investors, with Oxford Sciences Innovation and GV as the most recent investors. It operates a biotechnology platform intended to generate next-generation vaccines. The company's biotechnology platform is designed to develop vaccines using a proprietary protein superglue called SpyTag/SpyCatcher, which is used to attach antigens to VLPs. The goal of the technology is to provide medical institutions and research centers with a technology that could allow the development of better vaccines in less time.

SpyTag/SpyCatcher technology uses a protein from the bacterium Streptococcus pyogenes split into two parts. The SpyTag peptide can be bound to antigens and the SpyCatcher portion binds to a virus like particle (VLP). VLPs are multiprotein structure that mimic viruses but lack viral genomes and are not infectious. VLPS are used in vaccine development. The process involves binding antigens to the coat proteins of VLPS. The SpyTag/SpyCatcher technology aims to do this in a more controlled and reliable manner compared with conventional techniques. The two pieces of the original SpyTag/SpyCatcher protein bind back together and form an unbreakable covalent bond. The technology is based on the observation that bacterial proteins like pilins and adhesins have endogenous isopeptide bonds. The term “Plug-and-Display” is used for his ability to separate antigen and scaffold production through modular assembly.

The company is developing a vaccine against human cytomegalovirus (CMV) and they have initiated GMP manufacturing of their CMV candidate.

Timeline

February 2021
SpyBiotech raises a $32,500,000 series A round from Braavos Investment Advisers, Future Fund, Google Ventures, Oxford Investment Consultants, Oxford Sciences Innovation and UK Future Fund.
2017
Founded

Funding rounds

People

Name
Role
LinkedIn

Jing Jin

Co-Founder, CTO

Sumi Biswas

Founder, CEO, CSO

Further reading

Title
Author
Link
Type
Date

Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination

Theodora U. J. Bruun, Anne-Marie C. Andersson, Simon J. Draper, Mark Howarth

Journal

July 20, 2018

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Cormac Sheridan, Nature Biotechnology
April 30, 2021
Scientific American
Scientific American is the essential guide to the most awe-inspiring advances in science and technology, explaining how they change our understanding of the world and shape our lives.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.